Table 1.

Patient characteristics by response to immunosuppressive therapy, familial occurrence, and genetic findings

Patient CharacteristicsFirst-Year Treatment Response Information Available (%)First-Year Treatment Response Information Not Available (%)All, N=1354 (%)
Complete Remission, N=150Partial Remission, N=101No Remission, N=361Genetic/Familial, N=241Sporadic, N=501
Cause of disease
 Sporadic, no mutation identified92 (61.3)67 (66.3)228 (63.2)326 (65.1)713 (52.7)
 Sporadic, not tested45 (30.0)20 (19.8)50 (13.9)175 (34.9)290 (21.4)
 Genetic2 (1.3)8 (7.9)64 (17.7)138 (57.3)212 (15.7)
 Familial, no mutation identified11 (7.3)6 (5.9)19 (5.3)103 (42.7)139 (10.3)
Histopathologic diagnosis
 MCGN37 (28.0)24 (25.0)70 (21.0)16 (8.4)102 (25.3)249 (21.6)
 MesPGN15 (11.4)12 (12.5)44 (13.2)29 (15.2)44 (10.9)144 (12.5)
 FSGS74 (56.1)55 (57.3)202 (60.7)114 (59.7)220 (54.6)666 (57.6)
 DMS007 (2.1)12 (6.3)7 (1.7)26 (2.3)
 Other6 (4.5)5 (5.2)10 (3.0)20 (10.5)30 (7.4)72 (6.1)
 Unknown/no biopsy185285098199
Characteristics at disease onset
 Age
  >3 mo and <1 yr11 (7.3)1 (1.0)17 (4.7)40 (16.6)44 (8.8)113 (8.3)
  ≥1 and <6 yr90 (60.0)55 (54.5)194 (53.7)122 (50.6)265 (52.9)726 (53.6)
  ≥6 and <12 yr30 (20.0)25 (24.8)92 (25.5)44 (18.3)134 (26.7)325 (24.0)
  ≥12 yr19 (12.7)20 (19.8)58 (16.1)35 (14.5)58 (11.6)190 (14.0)
 Serum albumin, g/L18.9 (14.0–23.0)20.0 (15.1–29.0)19.5 (15.0–25.0)24.0 (17.5–35.0)20.0 (16.0–29.0)20.0 (16.0–28.0)
  Ninfo120892731713551008
 Proteinuria
  Nephrotic range124 (93.2)86 (92.5)315 (96.9)167 (86.5)336 (90.1)1028 (92.0)
  Non-nephrotic range9 (6.8)7 (7.5)10 (3.1)26 (13.5)37 (9.9)89 (8.0)
  Ninfo133933251933731117
 Renal function
  CKD stage 183 (69.7)61 (76.3)206 (69.6)78 (51.7)164 (57.1)592 (63.5)
  CKD stage 223 (19.3)14 (17.5)62 (20.9)35 (23.2)85 (29.6)219 (23.5)
  CKD stage 311 (9.2)5 (6.3)21 (7.1)29 (19.2)27 (9.4)93 (10.0)
  CKD stage 42 (1.7)07 (2.4)9 (6.0)11 (3.8)29 (3.1)
  Ninfo11980296151287933
Follow-up information
 Duration of follow-up, yr3.9 (1.5–6.3)3.2 (1.6–5.6)3.0 (1.2–5.7)3.5 (1.0–7.2)4.0 (1.8–7.8)3.6 (1.5–6.8)
 ESRD at last observation7 (4.7)12 (11.9)115 (31.9)116 (47.9)113 (22.6)363 (26.8)
 Time to ESRD, yr2.4 (0.8–4.8)3.3 (1.1–4.6)3.0 (1.6–5.3)3.0 (0.8–6.4)2.6 (0.8–5.8)2.8 (1.1–5.6)
 Renal survival, yr
  ≤12 (1.5)2 (2.3)20 (6.7)34 (15.7)30 (6.6)88 (7.4)
  >1130 (98.5)86 (97.7)279 (93.3)180 (84.1)422 (93.4)1097 (92.6)
  Ninfo132882992144521185
  • Data are given as N (percentage) per analysis group (column) or median (interquartile range). MCGN, minimal-change glomerulopathy; MesPGN, mesangioproliferative glomerulonephritis; DMS, diffuse mesangial sclerosis.